Multifunctional Nanoparticle Approach for Targeting Melanoma

Jun Li,Jun Xie,Jintao Zhu,Jun Tao
DOI: https://doi.org/10.1016/j.jisp.2018.09.011
2018-01-01
Journal of Investigative Dermatology Symposium Proceedings
Abstract:Malignant melanoma is the most aggressive and lethal form of skin cancer with an increasing incidence worldwide. In the past 5 years, the Food and Drug Administration has approved six targeted therapies or immunotherapies for the treatment of metastatic melanoma (Chapman et al., 2011; Falchook et al., 2012; Hauschild et al., 2012; Hodi et al., 2010; Ribas et al., 2015; Topalian et al., 2014). For the first time, interventions improve survival of this deadly disease. However, rapid resistance to BRAF/MEK inhibitors and lower rates of objective response or immune-related side effects for anti-CTLA-4 or anti-PD-1 monoclonal antibodies limited their widespread clinical applications.
What problem does this paper attempt to address?